Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats

Acta Pharmacologica Sinica

Volumn 32, Issue 3, 2011, Pages 321-328

  Xie, Fang ^a   Sun, Chao ^a,b   Sun, Li Hua ^a   Li, Jing Yuan ^a   Chen, Xin ^a   Che, Hui ^a   Lu, Guan Yi ^a   Yang, Bao Feng ^a   Ai, Jing ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

baroreflex sensitivity; cardiac function; diabetes; fluvastatin

Indexed keywords

CHOLESTEROL; FATTY ACID; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; BULIMIA; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE RELAXATION; HEART RATE VARIABILITY; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; NONHUMAN; OUTCOME ASSESSMENT; POLYDIPSIA; PRESSORECEPTOR REFLEX; RAT; RECEPTOR SENSITIVITY; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BAROREFLEX; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS, MONOUNSATURATED; HEART; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; RANDOM ALLOCATION; RATS;

EID: 79952375502     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.221     Document Type: Article

References (41)

1. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602
2. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy Circulation 2007; 115: 387-97 (Pubitemid 46148513)
3. De Angelis K, Schaan BD, Maeda CY, Dall'Ago P, Wichi RB, Irigoyen MC. Cardiovascular control in experimental diabetes. Braz J Med Bio Res 2002; 35: 1091-100. (Pubitemid 35476808)
4. El-Menyar AA. Dysrhythmia and electrocardiographic changes in diabetes mellitus: pathophysiology and impact on the incidence of sudden cardiac death. J Cardiovasc Med (Hagerstown) 2006; 7: 580-5 (Pubitemid 44350492)
5. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A Nohara R, et al. Barorefex sensitivity and heart rate variability in the identifcation of patients at risk for life-threatening arrhythmias mplications of clinical trials. Circulation 2001; 103: 2072-7 (Pubitemid 32373010)
6. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity FEBS Lett 1976; 72: 323-6 (Pubitemid 8017240)
7. Lawrence JM, Reckless JP. Fluvastatin. Expert Opin Pharmacother 2002; 3: 1631-41 (Pubitemid 35355893)
8. Christians U, Jacobsen W, Floren LC. Metabolism and drug interac-tions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34. (Pubitemid 28498199)
9. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New nsights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28
10. Corsini A, Jacobson TA, Ballantyne CM. Fluvastatin: clinical and safety profle. Drugs 2004; 64: 1305-23
11. Perreault S, Hamilton VH, Lavoie F, Grover S. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fbrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1997; 10: 787-94 (Pubitemid 27129783)
12. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsinin A. Pleiotropic effects of statins in atherosclerosis and diabetes Diabetes Care 2000; 23: B72-8 (Pubitemid 30185781)
13. Armpatzis CA, Goedhart D, Serruys PW, Saia F, Lemos PA, de Feyter P. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention\a Lescol Intervention Prevention Study (LIPS) substudy Am Heart J 2005; 149: 329-35 (Pubitemid 40348543)
14. Matsuki A, Nozawa T, Igarashi N, Sobajima M, Ohori T, Suzuki T, et al. Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circ J 2010; 74: 468-75
15. Imaeda A, Aoki T, Kondo Y, Hori M, Ogata M, Obayashi H, et al. Protective effects of fluvastatin against reactive oxygen species nduced DNA damage and mutagenesis. Free Radic Res 2001; 34: 33-44 (Pubitemid 32186121)
16. Ai J, Yan X, Zhao L, Lu Y, Liang F, Cai B, et al. The protective effect of Daming capsule on heart function in streptozocin-induced diabetic rats with hyperlipidemia. Biol Pharm Bull 2009; 32: 1354-8
17. Ai J, Liang F, Zhou H, Zhao J, Wang N, Zhu S, et al. Mechanism of impaired baroreflex sensitivity in Wistar rats fed a high-fat and-carbohydrate diet. Br J Nutr 2010; 104: 291-7.
18. Lin M, Liu R, Gozal D, Wead WB, Chapleau MW, Wurster R, et al. Chronic intermittent hypoxia impairs barorefex control of heart rate but enhances heart rate responses to vagal efferent stimulation in anesthetized mice. Am J Physiol Heart Circ Physiol 2007; 293 H997-1006
19. Patel KP, Zhang PL Baroreflex function in streptozotocin (STZ) nduced diabetic rats. Diabetes Res Clin Pract 1995; 27: 1-9.
20. Lin M, Ai J, Harden SW, Huang C, Li L, Wurster RD, et al. Impairment of barorefex control of heart rate and structural changes of cardiac ganglia in conscious streptozotocin (STZ)-induced diabetic mice Auton Neurosci 2010; 155: 39-48
21. Dall'ago P, D'Agord Schaan B, da Silva VO, Werner J, da Silva Soares PP, de Angelis K, et al. Parasympathetic dysfunction is associated with barorefex and chemorefex impairment in streptozotocin-induced diabetes in rats. Auton Neurosci 2007; 131: 28-35 (Pubitemid 44960173)
22. Meyrelles SS, Mauad H, Mathias SC, Cabral AM, Vasquez EC Effects of myocardial hypertrophy on neural refexes controlling cardiovascular function. J Auton Nerv Syst 1998; 73: 135-42 (Pubitemid 28529170)
23. Itagaki M, Takaguri A, Kano S, Kaneta S, Ichihara K, Satoh K. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fbroblasts and in rats. J Pharamacol Sci 2009; 109: 94-101.
24. Basic-Jukic N, Kes P, Bubic-Filipi L, Vranjican Z. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fuvastatin and rapamycin in a renal transplant recipient. Nephrol Dial Transplant 2010; 25: 2036; author reply 2036-7.
25. Chang KS, Lund DD. Alterations in the baroreceptor refex control of heart rate in streptozotocin diabetic rats. J Mol Cell Cardiol 1986; 18: 617-24 (Pubitemid 16090718)
26. Homma S, Yamazaki Y, Karakida T. Blood pressure and heart rate relationships during cervical sympathetic and vagus nerve stimulation in streptozotocin diabetic rats. Brain Res 1993; 629: 342-4 (Pubitemid 23337814)
27. Cohen AJ, McCarthy DM, Rossetti RR. Renin secretion by the spon-taneously diabetic rat. Diabetes 1986; 35: 341-6. (Pubitemid 16137006)
28. Dall'Ago P, Fernandes TG, Machado UF Belló AA, Irigoyen MC. Baro-reflex and chemoreflex dysfunction in streptozotocin-diabetic rats Braz J Med Biol Res 1997; 30: 119-24. (Pubitemid 27083285)
29. Maeda CY, Fernandes TG, Lulhier F, Irigoyen MC. Streptozotocin diabetes modifes arterial pressure and barorefex sensitivity in rats Braz J Med Biol Res 1995; 28: 497-501
30. Heistad DD, Abboud FM, Mark AL, Schmid PG. Interaction of baroreceptor and chemoreceptor reflexes. Modulation of the chemoreceptor refex by changes in baroreceptor activity J Clin Invest 1974; 53: 1226-36
31. Jackson CV, Carrier GO. Infuence of short-term experimental diabetes on blood pressure and heart rate in response to norepinephrine and angiotensin II in the conscious rat J Cardiovasc Pharmacol 1983; 5 260-5 (Pubitemid 13163104)
32. Shimokawa A, Kunitake T, Takasaki M, Kannan H. Differential effects of anesthetics on sympathetic nerve activity and arterial baroreceptor refex in chronically instrumented rats. J Auton Nerv Syst 1998; 72 46-54 (Pubitemid 28414401)
33. Van Leeuwen AF, Evans RG, Ludbrook J. Effects of halothane ketamine, propofol and alfentanil anaesthesia on circulatory control in rabbits. Clin Exp Pharmacol Physiol 1990; 17: 781-98
34. Maron DJ, Fazio S, Linton MF. Current perspectives on statins Circulation 2000; 101: 207-13 (Pubitemid 30044262)
35. Liao JK. Isoprenoids as mediators of the biological effects of statins J Clin Invest 2002; 110: 285-8 (Pubitemid 34847957)
36. Tawfk HE, EI-Remessy AB, Matragoon S, Ma G, Caldwell RB, Caldwel RW. Simvastatin improves diabetes-induced coronary endothelia dysfunction. J Pharmacol Exp Ther 2006; 319: 386-95 (Pubitemid 44455146)
37. Gao L, Wang W, Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther 2008; 326: 278-85 (Pubitemid 351872118)
38. Ballantyne CM, Riegger G, Moore N, Saia F, Serruys PW. Fluvastatin reduces cardiac mortality in patients with coronary heart disease Cardiovasc Drugs Ther 2004; 18: 67-75 (Pubitemid 38992600)
39. Riegger G, Abletshauser C, Ludwig M, Schwandt P, Widimsky J Weidinger G, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144: 263-70 (Pubitemid 29259987)
40. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful frst percutaneous coronary intervention: a randomized controlled trial JAMA 2002; 287: 3215-22 (Pubitemid 34686102)
41. Serruys PW, De Feyter PJ, Benghozi R, Hugenholtz PG, Lesaffre E. The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fuvastatin after successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent 2001; 4: 165-72 (Pubitemid 34538581)